7 completed, 2 terminated, 2 withdrawn. 7 Phase 2, 3 Phase 1, 2 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 2, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Not applicable | 2 | Completed 1, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Recurrent Skin Cancer: new trials by email Literature Review of Recurrent Skin Cancer trials Research Report on Recurrent Skin Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Buparlisib, Sonidegib - Carcinoma, Basal Cell, Recurrent Skin Cancer | Phase 2 | Terminated | Anne Chang | 10 | 2015-02-01 | 2019-01-29 |
| Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer cetuximab, laboratory biomarker analysis - Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin | Not applicable | Completed | Rutgers, The State University of New Jersey | 15 | 2015-01-30 | 2023-12-20 |
| Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma arsenic trioxide - Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer | Phase 1 / Phase 2 | Completed | Stanford University | 5 | 2013-04-01 | 2018-06-08 |
| Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Capecitabine - Squamous Cell Carcinoma of the Skin, Recurrent Skin Cancer | Phase 2 | Terminated | Stanford University | 2 | 2013-03-01 | 2018-04-12 |
| Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC) vismodegib, Mohs surgery - Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer | Early Phase 1 | Completed | Stanford University | 15 | 2012-06-01 | 2017-12-08 |
| Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma isolated limb perfusion, melphalan, quality-of-life assessment - Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin | Not applicable | Withdrawn | Albert Einstein College of Medicine | 2012-04-01 | 2015-07-23 | |
| Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) erlotinib hydrochloride, linsitinib, placebo - Recurrent Skin Cancer, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Phase 1 / Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2011-12-01 | 2014-11-19 | |
| Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer methyl-5-aminolevulinate hydrochloride cream, photodynamic therapy, laser therapy - Basal Cell Carcinoma of the Skin, Pain | Phase 1 | Completed | Roswell Park Cancer Institute | 21 | 2011-03-01 | 2014-09-29 |
| Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia dasatinib, laboratory biomarker analysis - Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin | Phase 2 | Completed | National Cancer Institute (NCI) | 7 | 2007-11-01 | 2015-06-18 |
| Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Gefitinib, Radiotherapy, Conventional surgery - Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2005-03-01 | 2019-08-30 |
| T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant liposomal T4N5 lotion, placebo, laboratory biomarker analysis - Actinic Keratosis, Basal Cell Carcinoma of the Skin | Phase 2 | Completed | National Cancer Institute (NCI) | 100 | 2004-03-01 | 2015-12-04 |
Skin Neoplasms (11) · Carcinoma, Basal Cell (6) · Basal Cell Nevus Syndrome (1) · Keratosis, Actinic (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Melanoma (1) · Pain (1) · Sarcoma (1)
Neoplasms (11) · Neoplasms by Site (11) · Skin Diseases (11) · Skin and Connective Tissue Diseases (11) · Neoplasms by Histologic Type (7) · Carcinoma (6) · Neoplasms, Basal Cell (6) · Neoplasms, Glandular and Epithelial (6) · Pathological Conditions, Signs and Symptoms (2) · Abnormalities, Multiple (1) · Bone Cysts (1) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Chronic Disease (1) · Congenital Abnormalities (1)
Radiation (2) · Radiotherapy (2) · 1-phenyl-3,3-dimethyltriazene (1) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · Arsenic Trioxide (1) · Capecitabine (1) · Cetuximab (1) · Congresses as Topic (1) · Dasatinib (1) · Deoxyribonuclease (Pyrimidine Dimer) (1) · Erlotinib Hydrochloride (1) · Gefitinib (1) · HhAntag691 (1) · Laser Therapy (1) · Melphalan (1)
National Cancer Institute (NCI) (3) · Stanford University (3) · Albert Einstein College of Medicine (1) · Anne Chang (1) · OHSU Knight Cancer Institute (1) · Roswell Park Cancer Institute (1) · Rutgers, The State University of New Jersey (1)
United States (11)
Adam Berger, MD (1) · Alexander Colevas (1) · Anne Lynn Chang, MD (1) · Craig Elmets (1) · Ilene L Rothman, MD (1) · Jean Tang (1) · Jean Tang, MD (1) · Katia Papalezova (1) · Neil Gross (1) · Randal Weber (1) · Thomas Olencki (1)
N01CM00070 (1), P30CA013330 (1), P30CA016058 (1), P30CA072720 (1)